These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Treatment of glycemic control in diabetes in the CVOT era. Einhorn D J Diabetes; 2020 Jan; 12(1):4. PubMed ID: 31746129 [No Abstract] [Full Text] [Related]
43. Guidelines for glycemic control. Clement S Clin Cornerstone; 2004; 6(2):31-9. PubMed ID: 15628691 [TBL] [Abstract][Full Text] [Related]
46. [Diabetes: glycemic targets and over-treatment in older patients]. Deletre S; Coutaz M Rev Med Suisse; 2016 Mar; 12(508):461-4, 466. PubMed ID: 27089604 [TBL] [Abstract][Full Text] [Related]
47. Home glucose monitoring makes little difference in type 2 diabetes. J Fam Pract; 2005 Nov; 54(11):936. PubMed ID: 16299946 [No Abstract] [Full Text] [Related]
48. Should A1C targets be individualized for all people with diabetes? Arguments for and against. Teoh H; Home P; Leiter LA Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S191-6. PubMed ID: 21525454 [No Abstract] [Full Text] [Related]
49. [Insulin therapy: basic concepts for care]. Gil Zorzo E Rev Enferm; 1999 Mar; 22(3 Suppl):12-5. PubMed ID: 10437561 [No Abstract] [Full Text] [Related]
50. The evolution of insulin therapy in diabetes mellitus. Heile M; Schneider D J Fam Pract; 2012 May; 61(5 Suppl):S6-12. PubMed ID: 22577636 [No Abstract] [Full Text] [Related]
51. Glycaemic Control and Associated Self-Management Behaviours in Diabetic Outpatients: A Hospital Based Observation Study in Lusaka, Zambia. Musenge EM; Michelo C; Mudenda B; Manankov A J Diabetes Res; 2016; 2016():7934654. PubMed ID: 26798654 [TBL] [Abstract][Full Text] [Related]
55. New perspectives on insulin therapy. Araki E; Araki H; Senokuchi T; Motoshima H J Diabetes Investig; 2020 Jul; 11(4):795-797. PubMed ID: 32232932 [No Abstract] [Full Text] [Related]
56. [Update on materials related to diabetic monitoring]. Rev Infirm; 2000 Apr; (59):24-6. PubMed ID: 11075169 [No Abstract] [Full Text] [Related]
57. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Bruhn D; Martin AA; Tavares R; Hunt B; Pollock RF J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484 [TBL] [Abstract][Full Text] [Related]
58. Impact of a reduced error range of SMBG in insulin-treated patients in Germany. Schnell O; Erbach M J Diabetes Sci Technol; 2014 May; 8(3):479-82. PubMed ID: 24876609 [TBL] [Abstract][Full Text] [Related]
59. Blood glucose monitoring: reducing the cost, increasing the benefit. Holt P Br J Community Nurs; 2007 Aug; 12(8):337-41. PubMed ID: 17851297 [TBL] [Abstract][Full Text] [Related]
60. Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia in insulin-dependent diabetic patients. Darling JD; O'Donnell TFX; Deery SE; Norman AV; Vu GH; Guzman RJ; Wyers MC; Hamdan AD; Schermerhorn ML J Vasc Surg; 2018 Nov; 68(5):1455-1464.e1. PubMed ID: 30360841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]